Richard Prest

Rich Prest advises and connects our life sciences clients with the broad range of services Avalere offers.

He leads efforts to support new customers and to bring our data and analytics services to more organizations. He has deep expertise in commercialization, market access, and digital health.

Prior to joining Avalere and since arriving in the US from Australia in 1999, Rich has led corporate strategy for AssistRx, been a senior principal consultant for the Blue Fin Group, led strategy for Edge Dynamics, and led product management for Abilizer Solutions.

Rich has a MBA from Melbourne Business School, a BArch with Honors from the University of Melbourne, and a BEng with Honors from the University of Adelaide.

Authored Content

In this segment, our experts welcome leaders from Jazz Pharmaceuticals and Coherus BioSciences to discuss the selection process and key learnings and considerations for working with a third-party logistics (3PL) company.

Crises often drive change at a pace not thought feasible in normal times. The COVID-19 pandemic has been no exception, bringing the accelerated development and emergency approval of vaccines, the wide implementation of telehealth, and potentially permanent changes to the way that global business is conducted.

Digital health solutions continue to advance the way healthcare is delivered. Through research and development as well as stakeholder partnerships, life science companies can leverage digital health technologies to optimize access along the patient care journey.

Manufacturers currently in the developmental phase for drug assets targeting rare or orphan diseases should assess the commercialization implications when bringing novel therapies to market and how they may differ from the standard pharmaceutical supply chain and economics.